Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 20/20 | 0.71 |
| ▸ | HRH1 | P35367 | 8/20 | 0.71 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567409 | 0.93 | SSTR5 (0.68) | SSTR5HRH1SSTR1KCNH2 | |
| SCHEMBL3583886 | 0.91 | SSTR5 (0.73) | SSTR5HRH1SSTR1KCNH2 | |
| SCHEMBL4954646 | 0.89 | SSTR5 (0.63) | SSTR5HRH1SSTR1KCNH2 | |
| SCHEMBL1378016 | 0.89 | SSTR5 (0.86) | SSTR5HRH1SSTR1KCNH2 | |
| SCHEMBL3572646 | 0.87 | SSTR5 (0.75) | SSTR5HRH1SSTR1KCNH2 | |
| SCHEMBL3583346 | 0.86 | SSTR5 (0.81) | SSTR5HRH1SSTR1KCNH2 | |
| SCHEMBL3586284 | 0.86 | SSTR5 (0.81) | SSTR5HRH1SSTR1KCNH2 | |
| SCHEMBL3573208 | 0.86 | SSTR5 (0.71) | SSTR5HRH1SSTR1KCNH2 | |
| SCHEMBL3571661 | 0.84 | SSTR5 (0.83) | SSTR5HRH1SSTR1KCNH2 | |
| SCHEMBL3572576 | 0.84 | SSTR5 (0.68) | SSTR5HRH1SSTR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101137660-B | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds | HOFFMANN LA ROCHE | 2011-06-15 | — | — | CN | disclosed |
| US-7645753-B2 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1858901-B1 | BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | EP | disclosed |
| CN-101137660-A | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives as antidiabetic compounds | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | CN | disclosed |
| US-20060205718-A1 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205718-A1 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | SSTR5, SSTR1, SSTR2 | SSTR5 1/4885HRH1 183/4885SSTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.